About Us
RAINs medical research and development is focused on serving the world with our innovative technology to fight against antimicrobial resistance or SUPERBUGS, widely recognized as the largest threat to global health. Why RAIN? Rain is a blessing to the earth as it brings life to all that it touches and this is exactly what our technology will do as we are completing scientific validation and preparing for the regulatory processes to bring our product to the GLOBAL market.
What we do...
RAIN Scientific is a biomedical engineering company focused on our platform technology that is a very unique combination device medical device. Our initial focus is to support the fight against SEPSIS and antimicrobial resistance...
Who we are...
A passionate and diverse group of professionals from both the medical and industrial sectors that have come together to launch our amazing technology, which once available, will make a significant impact on global health supporting the fight against some of the worst intravenous infectious diseases.
Who Is RAIN Scientific?
Research...
Rain Scientific Inc. is currently collaborating with leading research institutes focused on the fight against antimicrobial resistance (AMR) with our unique combination device that has multiple mechanisms of action against target pathogens. AMR is widely accepted as the largest threat to global health so we couldn't be more excited about the market we will serve.
Updates...
October 2021: RAIN has completed in vitro research which has shown solid efficacy against AMR pathogens. RAIN has also successfully completed early safety trials leading to our upcoming GCP Human Safety trials.
December 2022: RAINs regulatory team has completed their regulatory review of our technology, its best possible application, which has led to a clearly defined regulatory path forward.
Fall 2023: RAIN continues to work with our research collaborators and have nearly completed our advanced ex vivo and hollow fiber testing, which will followed with animal in vivo trails scheduled to begin Q1 - 2024.
We are excited about the where we are at and look forward to sharing more here as things continue to develop...